Baudax patents expiration
1. Anjeso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8512727 | BAUDAX | Nanoparticulate meloxicam formulations |
Dec, 2022
(1 year, 4 months ago) | |
| US10471067 | BAUDAX | Nanoparticulate meloxicam formulations |
Feb, 2024
(2 months ago) | |
| US10463673 | BAUDAX | Nanoparticulate meloxicam formulations |
Feb, 2024
(2 months ago) | |
| US10709713 | BAUDAX | Nanoparticulate meloxicam formulations |
May, 2030
(6 years from now) | |
| US11253478 | BAUDAX | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
May, 2030
(6 years from now) | |
| US9974746 | BAUDAX | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
May, 2030
(6 years from now) | |
| US10881663 | BAUDAX | Method of treating pain in elderly patients with mild renal impairment |
Mar, 2039
(14 years from now) | |
| US11458145 | BAUDAX | Methods of administering intravenous meloxicam in a bolus dose |
Mar, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 20, 2023 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 20 February, 2020
Treatment: Management of moderate-to-severe pain by intravenous injection; Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection in patients with mild...
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
ANJESO family patents
